Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
HCW Biologics (HCWB)
NASDAQ:HCWB
Holding HCWB?
Track your performance easily
HCWB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.40 - $2.18
Previous Close$0.6
Volume41.65K
Average Volume (3M)22.93K
Market Cap
$22.69M
Enterprise Value$31.43M
Total Cash (Recent Filing)$1.16M
Total Debt (Recent Filing)$9.90M
Price to Earnings (P/E)―
Beta-0.61
Next Earnings
Nov 06, 2024EPS Estimate
-$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding37,823,394
10 Day Avg. Volume49,381
30 Day Avg. Volume22,935
Standard Deviation0.20
R-Squared0.04
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)-3.53
Price to Sales (P/S)5.80
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.76
Enterprise Value/Gross Profit12.26
Enterprise Value/Ebitda-1.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
HCW Biologics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressHCW Biologics' clinical trials for HCW9218 are showing promising results with a 50% stable disease rate, which could indicate potential efficacy and advancement in treatment options.
Financial StabilityWith a projected cash runway extending into late 2024, HCW Biologics appears to be financially equipped to continue its research and development efforts without immediate capital concerns.
Strategic DevelopmentThe company's strategic plan to initiate a randomized Phase 2 study combining '9218 with standard chemotherapy in ovarian cancer patients underscores its commitment to addressing unmet medical needs and may lead to enhanced treatment protocols.
Bears Say
Legal IssuesAltor BioScience and NantCell's legal proceedings against HCW Biologics and Dr. Wong could potentially lead to significant financial strain due to arbitration costs.
Legal ProceedingsThe arbitration process involving Altor BioScience, NantCell, and HCW Biologics before JAMS introduces uncertainty and risk, which could adversely affect investor sentiment.
Stock PerformanceShares have been negatively impacted by a blend of market-wide factors coupled with the financial burden of ongoing legal disputes.
---
Ownership Overview
47.89% Insiders
1.21% Mutual Funds
1.40% Other Institutional Investors
49.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
HCWB FAQ
What was HCW Biologics’s price range in the past 12 months?
HCW Biologics lowest stock price was $0.40 and its highest was $2.18 in the past 12 months.
What is HCW Biologics’s market cap?
Currently, no data Available
When is HCW Biologics’s upcoming earnings report date?
HCW Biologics’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were HCW Biologics’s earnings last quarter?
HCW Biologics released its earnings results on Aug 14, 2024. The company reported -$0.18 earnings per share for the quarter, the consensus estimate of -$0.18 by $0.
Is HCW Biologics overvalued?
According to Wall Street analysts HCW Biologics’s price is currently Overvalued.
Does HCW Biologics pay dividends?
HCW Biologics does not currently pay dividends.
What is HCW Biologics’s EPS estimate?
HCW Biologics’s EPS estimate is -$0.13.
How many shares outstanding does HCW Biologics have?
HCW Biologics has 37,823,395 shares outstanding.
What happened to HCW Biologics’s price movement after its last earnings report?
HCW Biologics reported an EPS of -$0.18 in its last earnings report, expectations of -$0.18. Following the earnings report the stock price went down -13.793%.
Which hedge fund is a major shareholder of HCW Biologics?
Currently, no hedge funds are holding shares in HCWB
---
HCW Biologics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.87%
12-Months-Change
Fundamentals
Return on Equity
-344.32%
Trailing 12-Months
Asset Growth
-32.07%
Trailing 12-Months
Company Description
HCW Biologics
HCW Biologics Inc is a preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases. It is developing HCW9218 as an injectable immunotherapeutic for patients with solid tumors.
---
HCWB Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering HCWB
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-26.02%
reiterated a buy rating 2 months ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -26.02% per trade.
---